Acceleron Pharma
128 Sidney Street
Cambridge
Massachusetts
United States
412 articles about Acceleron Pharma
-
Acceleron Pharma To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of American Society of Clinical Oncology
5/15/2014
-
Acceleron Pharma Reports First Quarter 2014 Financial Results
5/15/2014
-
Acceleron Pharma To Present At 2014 UBS Global Healthcare Conference
5/12/2014
-
Acceleron Pharma To Host First Quarter 2014 Financial Results Conference Call And Webcast On May 15, 2014
5/8/2014
-
Acceleron Pharma, Celgene Corporation And Collaborators Announce Two Publications In Nature Medicine Describing Sotatercept And ACE-536 Therapeutic Potential In Beta-Thalassemia And Myelodysplastic Syndromes
3/24/2014
-
Acceleron Pharma To Present At The 21st Annual Future Leaders In The Biotech Industry Conference
3/20/2014
-
Acceleron Pharma And Celgene Corporation Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting
3/18/2014
-
Acceleron Pharma To Present At Cowen and Company 34th Annual Health Care Conference
2/27/2014
-
Acceleron Pharma Reports Fourth Quarter And Year Ended 2013 Financial Results
2/26/2014
-
Acceleron Pharma To Host Fourth Quarter And Year Ended 2013 Financial Results Conference Call And Webcast On February 26, 2014
2/19/2014
-
Acceleron Pharma To Present At 2014 Leerink Swann and Company Global Healthcare Conference
2/5/2014
-
Acceleron Pharma Announces Pricing Of Public Offering Of Common Stock
1/23/2014
-
Acceleron Pharma Commences Proposed Public Offering Of Common Stock
1/21/2014
-
Acceleron Pharma Files Registration Statement For Proposed Public Offering Of Common Stock
1/10/2014
-
Acceleron Pharma To Be Added To Russell 2000® Index
12/20/2013
-
Acceleron Pharma Earns $7 Million Milestone Payment For Celgene’s Initiation Of Sotatercept Phase 2 Clinical Trial In Patients With End Stage Renal Disease On Hemodialysis
12/18/2013
-
Acceleron Pharma And Celgene Report New Interim Clinical Data From Phase 2 Trial Of Sotatercept In Beta-Thalassemia At 2013 American Society of Hematology Annual Meeting
12/9/2013
-
Acceleron Pharma Provides Update On Clinical Pipeline At Piper Jaffray Healthcare Conference
12/3/2013
-
Acceleron Pharma Announces New Interim Phase 2 Sotatercept Clinical Data In Beta-Thalassemia To Be Presented At 2013 American Society of Hematology Annual Meeting
12/2/2013
-
Acceleron Pharma to Present at Piper Jaffray Healthcare Conference in December
11/25/2013